Solvonis Therapeutics plc

Research Solvonis Therapeutics plc (SVNS) on Bullrun: market cap GBX 829.47M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerSVNS
ExchangeLSE
CountryUnited Kingdom
SectorIndustrials
IndustrySpecialty Industrial Machinery
CurrencyGBX
Market capGBX 829.47M
Financial periodQ4 2024
RevenueGBP 0
Net income-GBP 335.00K
Free cash flow-GBP 149.00K

Valuation Snapshot

latest market cap is GBX 829.47M.

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-11	GBX 829.47M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 GBX.

About Solvonis Therapeutics plc

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder;

Related stock research

United Kingdom stocks United Kingdom Industrials stocks A-Z stock index

Other Industrials stocks

Advanced Innergy Holdings Ltd (AIH) Avingtrans Plc (AVG) Bodycote PLC (BOY) Castings PLC (CGS) Clean Power Hydrogen plc (CPH2.L) Goodwin PLC (GDWN) IMI PLC (IMI) ITM Power Plc (ITM.L) Morgan Advanced Materials plc (MGAM) MPAC Group PLC (MPAC) Melrose Industries PLC (MRO) PowerHouse Energy Group Plc (PHE)

Frequently asked questions

What is Solvonis Therapeutics plc's market cap?

Solvonis Therapeutics plc's market capitalization is GBX 829.47M.